US CDMO Cambrex has agreed to buy Snapdragon Chemistry, a compatriot company specializing in developing continuous flow and batch processes for APIs. Snapdragon is based...
Cambrex is investing in a new R&D facility in Minneapolis, Minnesota, USA, expanding its capacity for small molecule development and manufacturing.
US CDMO Cambrex has upgraded its facility in Tallin, Estonia. The installation of a new 160-liter reactor train at the kilogram-scale laboratory has expanded Cambrex’s...
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
Cambrex is spending $3.6 million to expand flexible drug substance manufacturing at its site in Karlskoga, Sweden. Engineering has already begun, and work is expected to...
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process...
- The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021. One important driver is the trend towards outsourcing of development and manu...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | Twitter